ABSTRACT

Herpes zoster (HZ), or shingles, is caused by the reactivation of latent varicella-zoster virus (VZV) from the sensory ganglia when VZV-specific T-cell immunity is decreased because of aging or immunosuppression. In the present study, we developed HZ DNA vaccine candidates encoding VZV proteins and cytokine adjuvants, such as IL-7 and IL-33. We immunized C57BL/6 mice with DNA plasmids encoding VZV glycoprotein E (gE), immediate early (IE) 63, or IE62 proteins and found that robust VZV protein-specific T-cell responses were elicited by HZ DNA vaccination. Co-administration of DNA plasmids encoding IL-7 or IL-33 in HZ DNA vaccination significantly enhanced the magnitude of VZV protein-specific T-cell responses. Protective immunity elicited by HZ DNA vaccination was proven by challenge experiments with a surrogate virus, vaccinia virus expressing gE (VV-gE). A single dose of HZ DNA vaccine strongly boosted gE-specific T-cell responses in mice with a history of previous infection by VV-gE. Thus, HZ DNA vaccines with IL-7 and IL-33 adjuvants strongly elicit protective immunity.

Keywords: Herpes zoster; T-cells; DNA vaccines; IL-7; IL-33

INTRODUCTION

Herpes zoster (HZ), or shingles, is caused by the reactivation of latent varicella-zoster virus (VZV) from the sensory ganglia (1,2). HZ develops when VZV-specific cell-mediated immunity (CMI) is decreased because of aging or immunosuppression (3,4). The estimated incidence of HZ is approximately 4 cases per 1,000 in those aged 50 to 60 years and increases to more than 10 cases per 1,000 for those aged >80 years (5). Lower VZV-specific CMI at HZ onset has been correlated with increased HZ severity and high incidence of complications (6). Therefore, VZV-specific CMI is thought to play a main role in controlling VZV reactivation and to contribute to protection against symptomatic HZ. Accordingly, the ability to elicit VZV-specific CMI is an important issue in the development of HZ vaccines (6,7).
Conflict of Interest
The authors declare no potential conflicts of interest.

Abbreviations
CMI, cell-mediated immunity; FBS, fetal bovine serum; gE, glycoprotein E; HZ, herpes zoster; IE, immediate early; IEDB, Immune Epitope Data Base; IFN, interferon; MHC, major histocompatibility complex; mIL-33, murine IL-33; mIL-7, murine IL-7; OLP, overlapping peptide; PFU, plaque-forming unit; TNF, tumor necrosis factor; VV-gE, vaccinia virus expressing glycoprotein E; VZV, varicella-zoster virus

Author Contributions
Conceptualization: Kim AR, Park J, Kim JH, Park SH, Shin EC; Formal analysis: Kim AR, Park J, Kim JH; Investigation: Kim AR, Park J, Kim JH; Methodology: Kim AR, Kwak JE, Cho Y, Lee H, Jeong M; Supervision: Park SH, Shin EC; Writing - original draft: Kim AR; Writing - review & editing: Shin EC.

A live attenuated VZV vaccine (Zostavax; Merck, Kenilworth, NJ, USA) has been available to prevent HZ since 2006. However, Zostavax has a limited vaccine efficacy depending on age (69.8% in those aged 50–59 years, 63.9% in those aged 60–69 years, 37.6% in those ≥70 years) (8,9). Moreover, the effectiveness of Zostavax decreases over time, from 68.7% in the first year after vaccination to approximately 4% by 8 years post-vaccination, which may account for the failure in eliciting long-term memory T-cell immunity after Zostavax vaccination (10,11).

A recombinant subunit vaccine containing VZV glycoprotein E (gE) protein and the AS01B adjuvant system (Shingrix, HZ/su; GSK, Philadelphia, PA, USA) was recently introduced as an alternative and approved by the US Food and Drug Administration in October 2017. Two doses of HZ/su vaccine have clinically acceptable safety profiles and high vaccine efficacy regardless of age (96.6% in those aged 50–59 years, 97.4% in those aged 60–69 years, and 97.9% in those aged ≥70 years) (12). Studies have demonstrated that HZ/su elicits robust gE-specific CD4+ T cell and antibody responses, even in older adults and immunocompromised patients (7,13,14). In a follow-up study, however, gE-specific CMI started to decline the first year after vaccination and fell to approximately 25% compared to the peak response between 36 and 72 months post-vaccination (15).

Since the first introduction in the early 1990s, DNA vaccines have been considered capable of inducing both cellular and humoral immune responses. In addition, DNA vaccines can easily be combined with other DNA plasmids encoding cytokines as molecular adjuvants (16). Notably, DNA vaccines have been suggested as an ideal therapeutic or prophylactic intervention, especially in chronic infectious diseases and cancers (17). DNA vaccines are currently being tested in clinical trials for the treatment of human papilloma virus-associated cervical cancer and breast cancer, and the prevention of human immunodeficiency virus and influenza infection (18-21).

IL-7 is a cytokine playing a significant role for T-cell homeostasis, particularly mediating the survival and expansion of naïve and memory T cells (22,23). Previous reports demonstrated that in vivo administration of IL-7 results in the increase of T-cell numbers as well as antigen-specific, functional T-cell responses (24-26). Furthermore, there are evidences that co-delivery of IL-7 as a vaccine adjuvant can enhance DNA vaccine-induced T-cell immune responses (27,28). IL-33 is a member of the IL-1 cytokine family and acts as an endogenous ‘danger signal’ that triggers inflammation and promotes cell-mediated immune responses (29). Recently, IL-33 has been reported to enhance DNA vaccine-induced, anti-tumor or antiviral T-cell immune responses (30,31).

In the present study, we developed DNA vaccine candidates encoding VZV proteins and cytokine adjuvants, such as IL-7 and IL-33. We used gE, immediate early (IE) 63, and IE62 as vaccine antigens because they have been defined as immunodominant proteins (32-34). We tested the immunogenicity in mice and found that HZ DNA vaccines induce VZV-specific functional T-cell responses, contributing to protective immunity in a surrogate challenge mouse model with vaccinia virus expressing gE (VV-gE). We further demonstrated that co-immunization with cytokine adjuvants enhanced HZ DNA vaccine-induced immunity. We observed that a single dose of HZ DNA vaccine had strong immune-boosting effects in mice with a history of previous infection by VV-gE. In summary, HZ DNA vaccines with cytokine adjuvants strongly elicit protective immunity.
MATERIALS AND METHODS

Animals
Five to six-week-old female C57BL/6 mice were purchased from Orientbio Inc. (Seongnam, Korea). All mice were maintained in specific pathogen-free conditions. Animal care and experimental procedures were performed with approval from the Animal Care Committee of Korea Advanced Institute of Science and Technology (KA2008-10).

DNA plasmids
Three different HZ DNA plasmids were generated using a modified pVAX1 mammalian expression vector and genes encoding gE (open reading frame, ORF 68), IE63 (ORF 63), and IE62 (ORF 62) of the pOka VZV strain. The genes encoding gE, IE63, and IE62 were genetically optimized for enhanced expression, including codon and RNA optimization, and a highly efficient immunoglobulin E leader sequence was added to facilitate expression. Each construct was synthesized commercially, sequence verified, and then the optimized gene was subcloned into a modified pVAX1 vector under control of the cytomegalovirus immediate-early promoter (GeneArt, Regensburg, Germany). The 3 HZ DNA plasmids were designated pVAX1-gE, pVAX1-IE63, and pVAX1-IE62, respectively. For cytokine DNA plasmids, the gene sequences for murine IL-7 (mIL-7) and murine IL-33 (mIL-33) were obtained from the NCBI GenBank Database and the genes synthesized. They were subcloned into a modified pVAX1 vector, designated pVAX1-mIL-7 and pVAX1-mIL-33.

Immunization
Five to 6-week-old female C57BL/6 mice were intramuscularly immunized 3 times at 2-week intervals with 30 µg pVAX1-gE, pVAX1-IE63, or pVAX1-IE62 in 100 µl of PBS, followed by in vivo electroporation using a CELLECTRA device (Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USA) on the external thigh. Control mice were immunized with 30 µg modified pVAX1 plasmid (pVAX1). Cytokine adjuvants (30 µg pVAX1-mIL-7 or pVAX1-mIL-33) were used simultaneously with HZ DNA vectors. Two weeks after the last immunization, mice were sacrificed, and their spleens obtained.

For the experiment of mice with a history of VV-gE infection, 6-week-old mice were intraperitoneally infected with 1×10^7 plaque-forming units (PFUs) of VV-gE in 100 µl PBS, maintained for 2 months, and DNA vaccination performed. Mice were sacrificed 2 weeks after the immunization and the spleens obtained.

Overlapping peptides
Overlapping peptides (OLPs; Mimotopes Pty Ltd., Melbourne, Australia) were synthesized as 15-mers overlapping by 10 amino acids to cover the whole amino acid sequence of gE, IE63, and IE62. Lyophilized peptides were solubilized in 5% DMSO (Sigma-Aldrich, St. Louis, MO, USA). OLPs were pooled as follows: gE-1 (1-41), gE-2 (42-82), gE-3 (83-123), IE63-1 (1-27), IE63-2 (28-54), IE62-1 (1-37), IE62-2 (38-74), IE62-3 (75-111), IE62-4 (112-148), IE62-5 (149-185), IE62-6 (186-223), and IE62-7 (224-261). The concentration of each peptide in the pools was 25 µg/ml, and finally diluted to 1 µg/ml in the splenocyte culture.

Interferon (IFN)-γ ELISPOT assays
IFN-γ ELISPOT assays were performed as described previously to measure antigen-specific IFN-γ secretion (35). The spleens of immunized mice were collected in RPMI-1640 medium (WelGENE, Daegu, Korea) supplemented with 5% fetal bovine serum (FBS) and 1x
penicillin-streptomycin, mechanically mashed, and filtered using 40 µm strainers. After centrifugation, cells were treated with RBC lysis buffer (BioLegend, San Diego, CA, USA) for 5 min at room temperature, washed, and then resuspended (0.5×10^6/well) in RPMI medium. Splenocytes were stimulated with OLP pools for 24 h. PMA (10 ng/ml, Sigma-Aldrich) and ionomycin (500 ng/ml, Sigma-Aldrich) were used as a positive control and 5% DMSO (Sigma-Aldrich) as a negative control. In addition to OLP pools, VZV-infected cell lysate (Microbix Biosystems, Mississauga, ON, Canada) was used as a stimulant, and non-infected MRC5 lysate (Microbix Biosystems) was used as a negative control. Spots were enumerated using an automated ELISpot reader (AID GmbH, Strassberg, Germany) and the number of specific spots calculated by subtracting the spot number in negative control wells from the spot number in OLP pool- or VZV lysate-stimulated wells.

**Intracellular cytokine staining**

Splenocytes were ex vivo stimulated with the immunodominant OLP pool, gE-1,4, I/63-2,35-54, and I/62-3,75-111 of gE, I/63, or I/62, respectively. To measure the degranulation activity of T cells, anti-CD107a-BV421 (1D4B; BioLegend) was added during the stimulation. Brefeldin A (GolgiPlug, BD Biosciences, San Jose, CA, USA) and monensin (GolgiStop, BD Biosciences) were added to the culture 1 h after the stimulation, and the culture was further maintained for 5 h. The Live/Dead Fixable Red Dead Cell stain kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), anti-CD3-Alexa Fluor 700 (500A2; eBioscience, Thermo Fisher Scientific), anti-CD4-BV786 (GK1.5; BD Biosciences), and anti-CD8-BV510 (53-6.7; BD Biosciences) were used for immunostaining at 4°C for 20 min. For intracellular staining, cells were permeabilized and fixed using the BD Cytofix/Cytoperm kit (BD Biosciences) at 4°C for 20 min, followed by staining with anti-IFN-γ-APC (XMG1.2; BioLegend), anti-tumor necrosis factor (TNF)-FITC (MP6-XT22; eBioscience), and anti-IL-2-PE (JES6-5H4; eBioscience) at 4°C for 20 min. All data were collected using a LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (Treestar, Ashland, OR, USA). Boolean gating was performed using FlowJo software to analyze the polyfunctionality of T cells, and charts were visualized by SPICE software (https://niaid.github.io/spice/).

**Epitope mapping and major histocompatibility complex (MHC) class I dextramer staining**

Because pVAX1-I/62-immunized mice exhibited a strong T-cell response against the I/62-3,75-111 OLP pool, we mapped T-cell epitopes within I/62-3,75-111. We performed IFN-γ ELISpot assays with splenocytes from pVAX1-I/62-immunized mice by stimulating them with a single peptide (15-mer; total 37 peptides). Peptides with high numbers of IFN-γ spots were identified, and the epitope sequence of high-affinity binding to mouse MHC class I, H-2D^b was identified using Immune Epitope Data Base (IEDB) website. The epitope peptide, RALINLIYC, was used for synthesis of H-2D^b dextramer (H-2D^b I/62 527-535 dextramer, ImmuneDex, Copenhagen, Denmark). Two weeks after the last immunization of pVAX1-I/62 with pVAX1-mIL-7 or pVAX1-mIL-33, splenocytes were stained with PE-conjugated H-2D^b 527-535 dextramer for 10 min at room temperature in the presence of anti-mouse CD16/32 (2.4G2; BD Biosciences), followed by washing with FACS buffer (PBS containing 1% FBS and 0.05% sodium azide). For live/dead and surface staining, the following reagent and antibodies were used: Live/Dead Fixable Red Dead Cell stain kit (Invitrogen), anti-CD19-PE-CF594 (ID3), anti-CD4-APC-Cy7 (GK1.5), anti-CD8-BV510 (53-6.7), anti-KLRG1 -Alexa Fluor 488 (2F1), anti-CD62L-BV605 (MEL-14; all from BD Biosciences), anti-CD44-BV650 (IM7), anti-CD69-BV711 (H1.2F3), anti-CD43-APC (1B11), anti-CD127-BV421 (A7R34; all from BioLegend), anti-CD27-PE-Cy7 (LG.7F9), and anti-CD3-Alexa Fluor 700 (500A2; all from eBioscience).
Recombinant vaccinia virus challenge and plaque assays

Recombinant VV-gE was used for *in vivo* challenge of a surrogate virus. Immunized mice were challenged intraperitoneally with 1×10⁷ PFU VV-gE in 100 µl PBS 14 days after the last vaccination. Mice were sacrificed 2 and 5 days after the challenge. Ovaries were harvested, placed in DMEM medium (WelGENE), and homogenized using Precellys 24 homogenizer (Bertin, Montigny-le-Bretonneux, France). Supernatants were collected and frozen at −70°C until plaque assays were performed. 143TK cells were grown on rat tail type I collagen (56 µg/well; Corning Inc., Corning, NY, USA)-coated 6-well plates to confluence. Ten-fold dilutions of the supernatants were added to the monolayer of 143TK cells and incubated at 37°C for 1 h. After removing diluted supernatants, DMEM supplemented with 5% FBS and 1× penicillin-streptomycin was added and left overnight. Staining was performed with 0.1% crystal violet after fixation with 1% paraformaldehyde. Plaques were counted and total viral load per ovary calculated.

Statistical analysis

Statistical analyses were performed using Prism software 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Unpaired Student *t*-tests (Mann-Whitney *U* test) were used to compare the results between two groups. To analyze the significance of polyfunctionality, 2-way ANOVA multiple comparisons were performed. Differences were considered significant when *p*<0.05 with a 95% confidence level.

RESULTS

HZ DNA vaccines induce VZV protein-specific T-cell immune responses

To investigate the immunogenicity of HZ DNA vaccines, C57BL/6 (B6) mice were intramuscularly immunized with pVAX1-gE, pVAX1-IE63, or pVAX1-IE62, followed by *in vivo* electroporation according to the schedule presented in Fig. 1A. When splenocytes from the immunized mice were stimulated with OLP pools corresponding to the immunized VZV ORF, IFN-γ ELISpot assays showed that all three DNA vaccines elicited robust T-cell responses against the antigen protein (Fig. 1B). Strong T-cell responses were also observed when splenocytes were stimulated with VZV-infected cell lysate (Fig. 1B). Next, we identified which T-cell subset responds to VZV proteins after HZ DNA vaccination by performing intracellular cytokine staining for IFN-γ, TNF, and IL-2. In the assays, splenocytes were stimulated with the immunodominant OLP pool for each VZV antigen protein as follows: gE-1-4, IE63-28-54, and IE62-37-111. pVAX1-gE elicited gE-specific production of IFN-γ, TNF, and IL-2 from CD4⁺ T cells, but not from CD8⁺ T cells (Fig. 1C). Similarly, pVAX1-IE63 induced a CD4⁺ T-cell response, but not CD8⁺ T-cell response, although IL-2 was not produced from CD4⁺ or CD8⁺ T cells (Fig. 1C). In contrast, pVAX1-IE62 elicited IE62-specific production of IFN-γ and TNF from both CD4⁺ and CD8⁺ T cells, and a high frequency of CD8⁺ T cells produced IFN-γ and TNF in response to IE62 (Fig. 1C). Thus, HZ DNA vaccines induced robust T-cell responses mediated mainly by either CD4⁺ or CD8⁺ T cells depending on the antigen protein.

IL-7 and IL-33 adjuvants enhance HZ DNA vaccine-induced T-cell immunity

Studies have shown that co-delivery of plasmids encoding cytokines can augment immune responses in DNA vaccination (36). In the present study, we tested IL-7 and IL-33 as molecular adjuvants in HZ DNA vaccination. Co-administration of plasmids encoding IL-7 or IL-33 have been reported to enhance DNA vaccine-induced T-cell responses (27,28,30,31). Mice were immunized with pVAX1-gE combined with pVAX1-mIL-7 or pVAX1-mIL-33, and gE-specific T-cell
Figure 1. T-cell immunogenicity of HZ DNA vaccines in C57BL/6 mice. Five to six-week-old female C57BL/6 mice were intramuscularly immunized three times at 2-week intervals with 30 µg pVAX1-gE, pVAX1-IE63, or pVAX1-IE62 in 100 µl of PBS, followed by in vivo electroporation (n=5 for each group). The control mice were immunized with 30 µg pVAX1 (n=3). The mice were sacrificed 2 weeks after the last immunization. (A) Immunization schedule. (B) IFN-γ ELISpot assays were performed to detect antigen-specific, IFN-γ-producing T cells by stimulating splenocytes from immunized mice with OLP pools corresponding to the immunized VZV ORF or VZV-infected cell lysate. (C) Intracellular cytokine staining for IFN-γ, TNF, and IL-2 was performed to detect antigen-specific, cytokine-producing CD4+ and CD8+ T cells by stimulating splenocytes from immunized mice with the immunodominant OLP pool for each VZV antigen protein (gE-1-41, IE63-28-54, and IE62-375-111). Data are presented as means and standard deviations.

*p<0.05.
responses evaluated by intracellular cytokine staining. As a result, pVAX1-gE immunization with both pVAX1-mIL-7 and pVAX1-mIL-33 elicited the strongest T-cell responses (Fig. 2A and B). Compared to pVAX1-gE alone, pVAX1-gE with both pVAX1-mIL-7 and pVAX1-mIL-33 significantly increased the TNF or IL-2 production by CD4+ T cells (Fig. 2B). pVAX1-gE with both pVAX1-mIL-7 and pVAX1-mIL-33 also significantly increased IFN-γ, TNF, or IL-2 production by CD4+ T cells compared to pVAX1-gE with pVAX1-mIL-7 (Fig. 2B). In polyfunctional T-cell analysis for IFN-γ, TNF, and IL-2, pVAX1-gE with both pVAX1-mIL-7 and pVAX1-mIL-33 tended to increase the percentage of triple- or double-positive T cells (Fig. 2C and D). In particular, pVAX1-gE with both pVAX1-mIL-7 and pVAX1-mIL-33 significantly enhanced the frequency of IFN-γ+TNF+CD4+ T cells compared to pVAX1-gE alone or pVAX1-gE with plasmids for a single cytokine (Fig. 2D).

We also tested IL-7 and IL-33 as molecular adjuvants in the pVAX1-IE62-induced CD8+ T-cell response. First, we attempted to identify a CD8+ T-cell epitope peptide in the immunodominant IE62 OLP pool, IE62-375-111, from pVAX1-IE62-immunized mice by performing IFN-γ ELISpot assays with single OLP stimulation. This assay revealed two subsequent OLPs, DPARQYRALINLIYC and YRALINLIYCPDRDP, as strong stimulants (Fig. 3A). In the overlapped sequence, we picked up RALINLIYC (IE62-527-535) as a high-affinity binder to H-2Dd using the IEDB website, and finally synthesized H-2DdIE62-527-535 dextramer. Using this dextramer, we successfully detected IE62-527-535-specific CD8+ T cells in pVAX1-IE62-immunized mice (Fig. 3B). Mice were then immunized with pVAX1-IE62 combined with pVAX1-mIL-7 or pVAX1-mIL-33, and the frequency of IE62-527-535-specific CD8+ T cells was evaluated by dextramer staining. As a result, pVAX1-IE62 immunization with both pVAX1-mIL-7 and pVAX1-mIL-33 elicited significantly higher CD8+ T-cell responses than pVAX1-IE62 alone (Fig. 3C). Taken together, the results indicate that co-administration of both pVAX1-mIL-7 and pVAX1-mIL-33 significantly enhanced both CD4+ and CD8+ T-cell responses in HZ DNA vaccination.

**T-cell responses elicited by HZ DNA vaccination are protective against a surrogate infection**

There is no appropriate mouse model for HZ because of host restriction of VZV. To evaluate whether HZ DNA vaccination induced protective immunity, we used VV-gE as a surrogate virus in challenge experiments. First, mice were immunized with pVAX1-gE with pVAX1-mIL-7 or pVAX1-mIL-33. Next, the mice were challenged with 1×10⁷ PFU VV-gE according to the schedule in Fig. 4A. The PFUs of VV-gE in the ovaries was determined 2 and 5 days after the challenge. Mice immunized with pVAX1-gE exhibited significant viral reduction compared to mice immunized with pVAX1 control plasmids, regardless of co-administration with pVAX1-mIL-7 or pVAX1-mIL-33 (Fig. 4B). Compared to pVAX1-gE alone, pVAX1-gE with pVAX1-mIL-33, or both pVAX1-mIL-7 and pVAX1-mIL-33 significantly decreased the viral titer 2 days post-infection (Fig. 4B). These data indicate that HZ DNA vaccination successfully induces protective immunity with additive benefits of IL-7 and IL-33 adjuvants.

**Single dose of HZ DNA vaccines boosts T-cell immunity in mice previously exposed to VV-gE**

Zoster vaccines are administered to hosts who are latently infected with VZV and already have VZV-specific T-cell immunity, though it was attenuated by aging or immunosuppression. To mimic this situation, mice were infected with 1×10⁷ PFU VV-gE. After recovery from the VV-gE infection, the mice were immunized with a single dose of HZ DNA vaccine according to the schedule in Fig. 5A. When T-cell responses were evaluated by IFN-γ ELISpot assays with stimulation of gE OLP pools, VV-gE infection did not result in detectable levels of T-cell responses 2 months after the infection. However, a single dose of pVAX1-gE strongly boosted
Figure 2. Adjuvant effects of IL-7 and IL-33 on HZ DNA vaccine-induced CD4+ T-cell immunity. Five to 6-week-old female C57BL/6 mice were intramuscularly immunized three times at 2-week intervals with 30 µg pVAX1-gE combined with 30 µg pVAX1-mIL-7 or pVAX1-mIL-33 in 100 µl of PBS, followed by in vivo electroporation (n=5 for each group). The control mice were immunized with 30 µg pVAX1 (n=3). Intracellular cytokine staining for IFN-γ, TNF, and IL-2 was performed to detect gE-specific, cytokine-producing CD4+ T cells by stimulating splenocytes from immunized mice with the gE-1-41 OLP pool. (A) Representative FACS dot plots. (B) Percentages of each cytokine-producing cell among CD4+ T cells for IFN-γ, TNF, and IL-2. Data are presented as means and standard deviations. (C) Pie graphs show the fraction of CD4+ T cells positive for a given number of functions. (D) CD4+ T cell polyfunctionality analyzed by every possible combination of functions and compared among groups. Means are presented.

*p<0.05; ***p<0.001.
gE-specific T-cell immunity regardless of the co-administration with pVAX1-mIL-7 or pVAX1-mIL-33 (Fig. 5B). Similar results were observed when splenocytes were stimulated by VZV-infected cell lysate (Fig. 5B). We also performed intracellular cytokine staining in the same setting. A single dose of pVAX1-gE immunization robustly boosted gE-specific production of IFN-γ, TNF, and IL-2 by CD4+ T cells regardless of the co-administration with pVAX1-mIL-7 or pVAX1-mIL-33, although VV-gE infection without HZ DNA immunization did not result in detectable levels of cytokine production by CD4+ T cells (Fig. 5C). These data indicate that even a single dose of HZ DNA vaccine robustly boosts VZV-specific T-cell immune responses in mice previously infected with VV-gE.
Here, we demonstrated that HZ DNA vaccination with IL-7 and IL-33 molecular adjuvants elicited protective T-cell immunity. Moreover, we showed that a single dose of HZ DNA vaccination robustly boosted VZV-specific T-cell responses in mice with a history of previous infection with VV-gE. Zostavax is a live attenuated vaccine that has been used in the elderly. However, the vaccine has limitations, including relatively low rates of prevention and declining vaccine efficacy with age. In addition, its use is contraindicated in immunocompromised people (37). HZ/su is a recombinant subunit vaccine containing gE protein and the AS01B adjuvant. HZ/su exhibits long-term, high vaccine efficacy regardless of the age of the host. However, Hu/su significantly induces gE-specific T-cell responses only when two-dose vaccination is performed (7). Therefore, HZ vaccines that vigorously induce VZV-specific T-cell responses with a single-dose vaccination and can be used safely for immunocompromised patients need to be developed.

We evaluated the T-cell immunogenicity of HZ DNA vaccines encoding VZV gE, IE63, or IE62 and found that HZ DNA vaccines robustly induce VZV-specific T-cell responses. Furthermore, the T-cell immunogenicity of HZ DNA vaccines was enhanced by co-administration of DNA
plasmids encoding IL-7 and IL-33. Previous studies have shown that co-delivery of plasmids encoding various cytokines substantially enhances DNA vaccine-induced immune responses in diverse settings (20, 38, 39). In particular, plasmids encoding IL-7 or IL-33 have been shown to significantly enhance DNA vaccine-induced T-cell responses (27, 28, 30, 31). In the current study, we evaluated the adjuvant effects of the combination of IL-7 and IL-33 for the first time and found that combined administration of IL-7 and IL-33 plasmids strongly enhanced HZ DNA vaccine-induced T-cell responses (Fig. 2). The strongest effect of the combination of IL-7
and IL-33 was also observed in the VV-gE challenge experiment, particularly at the early phase of infection (2 days post-infection; Fig. 4), indicating that HZ DNA vaccines co-administered with both IL-7 and IL-33 plasmids contribute to immediate protective immunity. This is important because high levels of immediate T-cell responses at the onset of HZ could attenuate the severity of HZ and the incidence of complications (6).

In the current study, we tried to assess the immune-boosting effects of HZ DNA vaccination in mice with a history of previous infection with VV-gE to mimic clinical situations, in which most people are latently infected with VZV and have pre-existing VZV-specific immunity (40). Similar experiments were performed during the development of HZ/su. Mice with a history of subcutaneous administration of live attenuated VZV were immunized with HZ/su; VZV-specific T-cell responses were strongly induced by vaccination with 2 doses of HZ/su (41). In contrast, a single dose of HZ DNA vaccine significantly increased VZV-specific T-cell responses in mice previously infected with VV-gE (Fig. 5). This result suggests that a single-dose regimen may be enough to prevent the development of HZ when HZ DNA vaccines are clinically developed.

The goal of HZ vaccination is to increase VZV-specific T-cell responses in order to prevent HZ and its complications. Here, we showed that HZ DNA vaccines induce strong VZV-specific T-cell responses, which are further enhanced by co-administration of plasmids for molecular cytokine adjuvants, such as IL-7 and IL-33. We also showed that HZ DNA vaccine-induced immunity is protective against virus infection using a surrogate virus. Importantly, a single dose of HZ DNA vaccination robustly boosts T-cell responses in mice with a history of previous infection by a surrogate virus. Thus, HZ DNA vaccination could be a promising strategy for prevention of HZ.

ACKNOWLEDGEMENTS

This work was supported by a grant from the National Research Foundation of Korea (NRF-2017R1A2A1A17069782), which is funded by the Ministry of Science and ICT, Republic of Korea.

REFERENCES

1. Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014;12:197-210.
2. Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013;26:728-743.
3. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349.
4. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014;348:g2911.
5. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-30.
6. Weinberg A, Zhang JH, Ozman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200:1068-1077.

7. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelïëre P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012;206:1280-1290.

8. Ozman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med 2005;352:2271-2284.

9. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012;54:922-928.

10. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016;213:1872-1875.

11. Qi Q, Cavanagh MM, Le Saux S, Wagar LE, Mackey S, Hechter RC, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016;213:1872-1875.

12. Cunningham AL, Heineman TC, Lal H, Godaex O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, et al. Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older. J Infect Dis 2018;217:1750-1760.

13. Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC, Brockmeyer N; Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015;211:1279-1287.

14. Stadmayer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicoleau GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, et al. A phase 1/2 study of an adjuvanted varicella-zoster vaccine subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 2014;124:2921-2929.

15. Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 2016;34:863-868.

16. Kutuzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9:776-788.

17. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011;53:296-302.

18. Trimble CL, Morrow MP, Krajensz KA, Chen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015;386:2078-2088.

19. Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AR, Gao F, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res 2014;20:5964-5975.

20. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, et al. Safety and comparative immunogenicity of an HIV1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013;208:818-829.
21. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Maut T, Nolan A, Zambon M, Ellis J, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase Ib clinical trial. *Vaccine* 2009;27:2506-2512. [PUBMED] [CROSSREF]

22. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzer J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J, et al. A potential role for interleukin-7 in T-cell homeostasis. *Blood* 2001;97:2983-2990. [PUBMED] [CROSSREF]

23. Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. *Nat Immunol* 2000;1:426-432. [PUBMED] [CROSSREF]

24. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM, Rouzioux C, Avettand-Fenoël V, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. *J Clin Invest* 2009;119:997-1007. [PUBMED] [CROSSREF]

25. Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. *Clin Cancer Res* 2010;16:727-735. [PUBMED] [CROSSREF]

26. Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. *Blood* 2012;120:4882-4891. [PUBMED] [CROSSREF]

27. Park SH, Song MY, Nam HJ, Im SJ, Sung YC. Codelivery of il-7 augments multigenic hcv DNA vaccine-induced antibody as well as broad t cell responses in cynomolgus monkeys. *Immune Netw* 2010;10:198-205. [PUBMED] [CROSSREF]

28. Sin JI, Kim J, Pachuk C, Weiner DB. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. *Clin Diagn Lab Immunol* 2000;7:751-758. [PUBMED] [CROSSREF]

29. Villarreal DO, Weiner DB. Interleukin 33: a switch-hitting cytokine. *Curr Opin Immunol* 2014;28:102-106. [PUBMED] [CROSSREF]

30. Villarreal DO, Wise MC, Walters IN, Reuschem EL, Choi MI, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. *Cancer Res* 2014;74:1789-1800. [PUBMED] [CROSSREF]

31. Villarreal DO, Svoronos N, Wise MC, Shedlock DJ, Morrow MP, Conejo-Garcia JR, Weiner DB. Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. *Vaccine* 2015;33:4313-4320. [PUBMED] [CROSSREF]

32. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. *Clin Exp Immunol* 2008;152:522-531. [PUBMED] [CROSSREF]

33. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. *J Infect Dis* 2003;188:40-52. [PUBMED] [CROSSREF]

34. Jones L, Black AP, Malavige GN, Ogg GS. Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. *Eur J Immunol* 2007;37:3393-3403. [PUBMED] [CROSSREF]

35. Choi YS, Lee DH, Shin EC. Relationship between poor immunogenicity of HLA-A2-restricted peptide epitopes and paucity of naïve CD8+ T-cell precursors in HLA-A2-transgenic mice. *Immuune Netw* 2014;14:219-225. [PUBMED] [CROSSREF]

36. Degen W, Schijns VE. Host-derived cytokines and chemokines as vaccine adjuvants. In: Immunopotentiators in Modern Vaccines, 2nd ed. Schijns VE, O’Hagan DT, eds. Amsterdam; Elsevier; 2017. p.65-84. [PUBMED] [CROSSREF]

37. Wang L, Zhu L, Zhu H. Efficacy of varicella (VZV) vaccination: an update for the clinician. *Ther Adv Vaccines* 2016;4:20-31. [PUBMED] [CROSSREF]
38. Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, et al. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of hepatitis C virus infection. Sci Rep 2017;7:43531.

39. Sun Y, Peng S, Yang A, Farmer E, Wu TC, Hung CF. Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation. Gene Ther 2017;24:408-415.

40. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010;48 Suppl 1:S2-S7.

41. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012;30:3126-3135.